共 50 条
Budget Saving Potential of Pegfilgrastim Biosimilar for the Treatment of Chemotherapy-Induced Febrile Neutropenia, in Italy
被引:0
|作者:
Berto, Patrizia
[1
]
Bellone, Marco
[2
]
Sabinot, Alice
[2
]
Pinto, Carmine
[3
]
Martino, Massimo
[4
]
Generali, Daniele
[4
]
Carriero, Pier Luigi
[5
]
Sanna, Maria Domenica
[1
]
机构:
[1] Regulatory Pharma Net Srl, Pisa, Italy
[2] AdRes HE&OR, Turin, Italy
[3] AUSL IRCCS, Med Oncol Unit, Comprehens Canc Ctr, Reggio Emilia, Italy
[4] Univ Trieste, Cattinara Hosp, Dept Med Surg & Hlth Sci, Trieste, Italy
[5] Accord Healthcare Italy, Milan, Italy
关键词:
Biosimilars;
Budget Impact Analysis;
Cost saving;
Febrile neutropenia;
Granulocyte colony stimulating factor (G-CSF);
COLONY-STIMULATING FACTORS;
CANCER-PATIENTS;
BREAST-CANCER;
ELDERLY-PATIENTS;
DAILY FILGRASTIM;
PRIMARY PROPHYLAXIS;
CLINICAL-PRACTICE;
G5;
COUNTRIES;
IMPACT;
METAANALYSIS;
D O I:
10.7175/fe.v23i1.1516
中图分类号:
R19 [保健组织与事业(卫生事业管理)];
学科分类号:
摘要:
INTRODUCTION: Current Italian guidelines recommend prophylaxis with granulocyte colony-stimulating factors (G-CSFs) to reduce the risk of chemotherapy-induced febrile neutropenia (FN). The availability of G-CSF biosimilars represents an opportunity for savings in the Italian National Healthcare Service (NHS) delivery of care. OBJECTIVE: To assess the cost saving potential associated with the introduction of pegfilgrastim biosimilars to local formularies, compared to the current G-CSF standard practice in Italy. METHODS: A budget impact model was developed to compare the current standard practice of long-acting (LA) and shortacting (SA) G-CSFs use, with a titture scenario in which the market share of LA G-CSFs grows due to the more advantageous administration schedule and price of pegfilgrastim biosimilar. The analysis included G-CSF treatment schedules, drug acquisition costs and costs of patient management including hospitalization and ambulatory care. RESULTS: The introduction of pegfilgrastim biosimilar resulted in cumulative 3-year cost savings off. 59,650 and E 41,539 for FN prophylaxis in a potential cohort of 1000 patients with solid tumors and lymphomas, respectively. CONCLUSIONS: The results indicate that the introduction of pegfilgrastim biosimilar is potentially associated with substantial cost savings for the Italian healthcare system.
引用
收藏
页码:1 / 12
页数:12
相关论文